President Donald Trump has announced an MFN pricing deal with Regeneron to lower prescription drug prices that Americans pay for some of the world's most innovative drugs, in line with the lowest prices paid by other developed nations, known as the most-favored-nation, or MFN, price.
You will be redirected in 10 seconds.